UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $6.99 Million Stock Position in Aspen Aerogels, Inc. (NYSE:ASPN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Aspen Aerogels, Inc. (NYSE:ASPN - Free Report) by 47.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 588,395 shares of the construction company's stock after acquiring an additional 188,861 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.72% of Aspen Aerogels worth $6,990,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in Aspen Aerogels by 5.5% during the fourth quarter. Vanguard Group Inc. now owns 4,360,246 shares of the construction company's stock worth $51,800,000 after buying an additional 226,251 shares during the last quarter. Barclays PLC lifted its holdings in shares of Aspen Aerogels by 16.8% in the 4th quarter. Barclays PLC now owns 107,764 shares of the construction company's stock worth $1,280,000 after acquiring an additional 15,462 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Aspen Aerogels by 645.4% in the fourth quarter. BNP Paribas Financial Markets now owns 135,584 shares of the construction company's stock worth $1,611,000 after buying an additional 117,395 shares during the period. Swiss National Bank increased its stake in shares of Aspen Aerogels by 1.9% in the fourth quarter. Swiss National Bank now owns 128,800 shares of the construction company's stock worth $1,530,000 after buying an additional 2,400 shares during the period. Finally, MetLife Investment Management LLC grew its position in shares of Aspen Aerogels by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 35,782 shares of the construction company's stock worth $425,000 after buying an additional 2,118 shares during the period. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Barclays restated an "equal weight" rating and set a $7.00 price objective (down from $13.00) on shares of Aspen Aerogels in a research note on Thursday, May 29th. Craig Hallum cut their price objective on shares of Aspen Aerogels from $21.00 to $18.00 and set a "buy" rating for the company in a report on Friday, February 14th. Canaccord Genuity Group cut their target price on shares of Aspen Aerogels from $20.00 to $15.00 and set a "buy" rating for the company in a report on Friday, February 14th. TD Cowen raised shares of Aspen Aerogels to a "strong-buy" rating in a research note on Tuesday, March 11th. Finally, Wall Street Zen raised shares of Aspen Aerogels to a "sell" rating in a research note on Wednesday, February 19th. One analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $18.44.

Aspen Aerogels Trading Down 2.1%

NYSE ASPN traded down $0.13 during trading on Thursday, hitting $5.79. The stock had a trading volume of 1,241,479 shares, compared to its average volume of 2,007,881. Aspen Aerogels, Inc. has a twelve month low of $4.16 and a twelve month high of $33.15. The company has a market capitalization of $474.98 million, a PE ratio of 36.16 and a beta of 2.72. The company has a quick ratio of 2.48, a current ratio of 2.93 and a debt-to-equity ratio of 0.27. The firm has a 50 day moving average price of $5.65 and a 200 day moving average price of $9.17.

Aspen Aerogels (NYSE:ASPN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The construction company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. Aspen Aerogels had a return on equity of 7.49% and a net margin of 2.95%. The business had revenue of $78.72 million during the quarter, compared to analysts' expectations of $82.75 million. During the same quarter in the prior year, the business earned ($0.02) earnings per share. The company's quarterly revenue was down 16.7% compared to the same quarter last year. As a group, equities research analysts forecast that Aspen Aerogels, Inc. will post 0.17 earnings per share for the current year.

Insider Activity at Aspen Aerogels

In other Aspen Aerogels news, CEO Donald R. Young purchased 20,000 shares of Aspen Aerogels stock in a transaction on Monday, May 12th. The stock was bought at an average price of $5.35 per share, for a total transaction of $107,000.00. Following the transaction, the chief executive officer now owns 550,856 shares of the company's stock, valued at $2,947,079.60. The trade was a 3.77% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.30% of the company's stock.

Aspen Aerogels Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.